Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
McCune TR et al. | Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. | 1998 | Transplantation | pmid:9448150 |
Mentzer RM et al. | Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. | 1998 | Transplantation | pmid:9448154 |
Busuttil RW and Lake JR | Role of tacrolimus in the evolution of liver transplantation. | 2004 | Transplantation | pmid:15201686 |
First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
Vincenti F | A decade of progress in kidney transplantation. | 2004 | Transplantation | pmid:15201687 |
Bunnapradist S et al. | Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. | 2003 | Transplantation | pmid:12865780 |
Asberg A et al. | Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. | 2006 | Transplantation | pmid:16861943 |
Pfitzmann R et al. | Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. | 2003 | Transplantation | pmid:12865798 |
Drachenberg CB et al. | Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. | 1999 | Transplantation | pmid:10459544 |
Gonwa T et al. | Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. | 2003 | Transplantation | pmid:12829910 |
Vu MD et al. | Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. | 1997 | Transplantation | pmid:9422432 |
Chaftari AM et al. | Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. | 2012 | Transplantation | pmid:22814329 |
Savoldo B et al. | Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. | 2001 | Transplantation | pmid:11579304 |
Sanchez-Campos S et al. | Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. | 1998 | Transplantation | pmid:9679826 |
Tsuchiya T et al. | Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. | 2013 | Transplantation | pmid:23792649 |
Iyengar AR et al. | Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. | 1997 | Transplantation | pmid:9158008 |
Størset E et al. | Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. | 2015 | Transplantation | pmid:25886918 |
Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518974 |
Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
Bronster DJ et al. | Tacrolimus-associated mutism after orthotopic liver transplantation. | 2000 | Transplantation | pmid:11014653 |
Burroughs TE et al. | Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. | 2009 | Transplantation | pmid:19667939 |
Mittal SK et al. | Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. | 2009 | Transplantation | pmid:19667950 |
Pérgola PE et al. | Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. | 2001 | Transplantation | pmid:11349738 |
Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
Xie Y et al. | Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. | 2017 | Transplantation | pmid:28187014 |
Sato T et al. | Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. | 2003 | Transplantation | pmid:14627910 |
Hooper DK et al. | Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. | 2012 | Transplantation | pmid:22491658 |
Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. | 2008 | Transplantation | pmid:18622280 |
Homma M et al. | Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. | 2002 | Transplantation | pmid:11821750 |
Inoue T et al. | Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. | 2000 | Transplantation | pmid:11003356 |
Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
Shapiro R et al. | "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. | 1996 | Transplantation | pmid:8932264 |
de Fijter JW | Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? | 2011 | Transplantation | pmid:21654351 |
Nankivell BJ et al. | Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. | 2016 | Transplantation | pmid:27306529 |
Neuhaus P et al. | Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. | 2000 | Transplantation | pmid:10868638 |
De Ruvo N et al. | Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. | 2005 | Transplantation | pmid:16003226 |
Mohamed MA et al. | TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. | 2000 | Transplantation | pmid:10755567 |
Reich DJ et al. | Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. | 2005 | Transplantation | pmid:16003228 |
Guthery SL et al. | Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. | 2003 | Transplantation | pmid:12698085 |
Guasch A et al. | Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. | 2010 | Transplantation | pmid:20811320 |
Wennberg L et al. | Preapheresis immunosuppressive induction: necessary or harmful? | 2007 | Transplantation | pmid:18162987 |
Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. | 2004 | Transplantation | pmid:14742990 |
Azzola A et al. | Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. | 2004 | Transplantation | pmid:14742993 |
Chavin KD et al. | Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. | 1994 | Transplantation | pmid:7511258 |
Hoerning A et al. | Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. | 2015 | Transplantation | pmid:25099702 |
Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
Zhang W et al. | Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. | 2017 | Transplantation | pmid:28885495 |
Guitard J et al. | Predictive factors for anemia six and twelve months after orthotopic liver transplantation. | 2006 | Transplantation | pmid:16770241 |